BioCryst's gout treatment demonstrates sustained 24-wk efficacy in extension study
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals revealed that its oral gout drug candidate BCX4208, in conjunction with the standard gout therapy allopurinol, demonstrated positive long-term results in the extension phase of its randomised Phase IIb study. Patients who received the therapy had failed to reach the serum acid therapeutic goal of less than 6mg/dl on allopurinol alone.